Scholarlink

Background <p>Tripartite motif-containing 37 (TRIM37) is an E3 ubiquitin ligase that epigenetically silences tumor suppressors in DNA repair, regulates polo-like kinase 4, promotes chromosomal instability, and functions as an oncogenic driver in breast cancer (BC). Preclinical studies have implicated TRIM37 in chemotherapy resistance, particularly in triple-negative breast cancer (TNBC), and TRIM37-targeted therapy is in development. However, TRIM37 has not been fully investigated in patients with BC, so its prognostic and therapeutic significance remains unclear.</p> Patients and Methods <p><i>TRIM37</i> expression was analyzed in 6558 patients across four large, independent cohorts with transcriptome data (METABRIC, TCGA, SCAN-B, and GSE25066).</p> Results <p><i>TRIM37</i> expression was higher in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative BC than in TNBC, and it was associated with worse disease-free, disease-specific, and overall survival in ER-positive/HER2-negative BC but not in TNBC. <i>TRIM37</i> expression was significantly associated with DNA repair pathways, homologous recombination deficiency, mutation rates, and enhanced cancer cell proliferation, as evidenced by Nottingham histological grade, Ki67 expression, and gene set enrichment analysis. <i>TRIM37</i> expression correlated with reduced immune activity, lower cytolytic activity, and decreased response to neoadjuvant chemotherapy in ER-positive/HER2-negative BC, whereas <i>TRIM37</i>-high TNBC displayed higher neoantigen burden and improved chemotherapy response.</p> Conclusion <p><i>TRIM37</i> expression is associated with increased cell proliferation, regardless of subtype; however, it is strongly associated with reduced immune activity, worse response to chemotherapy, and poor prognosis in ER-positive/HER2-negative BC, whereas it was associated with better response to chemotherapy and no relationship with survival in TNBC. Our results provide critical insights into the clinical application of TRIM37-targeted therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

TRIM37 Expression is Associated with Immune Suppression Poor Response to Neoadjuvant Chemotherapy and Worse Survival in ER-Positive/HER2-Negative Breast Cancer

  • 期刊论文

  • 发表日期：

    2025年11月21日

查看全文
  • Junko Tsuchida,
  • Rongrong Wu,
  • Masayuki Nagahashi,
  • John M. L. Ebos,
  • Takashi Ishikawa,
  • Masafumi Shimoda,
  • Toshifumi Wakai,
  • Kazuaki Takabe

摘要

Background

Tripartite motif-containing 37 (TRIM37) is an E3 ubiquitin ligase that epigenetically silences tumor suppressors in DNA repair, regulates polo-like kinase 4, promotes chromosomal instability, and functions as an oncogenic driver in breast cancer (BC). Preclinical studies have implicated TRIM37 in chemotherapy resistance, particularly in triple-negative breast cancer (TNBC), and TRIM37-targeted therapy is in development. However, TRIM37 has not been fully investigated in patients with BC, so its prognostic and therapeutic significance remains unclear.

Patients and Methods

TRIM37 expression was analyzed in 6558 patients across four large, independent cohorts with transcriptome data (METABRIC, TCGA, SCAN-B, and GSE25066).

Results

TRIM37 expression was higher in estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative BC than in TNBC, and it was associated with worse disease-free, disease-specific, and overall survival in ER-positive/HER2-negative BC but not in TNBC. TRIM37 expression was significantly associated with DNA repair pathways, homologous recombination deficiency, mutation rates, and enhanced cancer cell proliferation, as evidenced by Nottingham histological grade, Ki67 expression, and gene set enrichment analysis. TRIM37 expression correlated with reduced immune activity, lower cytolytic activity, and decreased response to neoadjuvant chemotherapy in ER-positive/HER2-negative BC, whereas TRIM37-high TNBC displayed higher neoantigen burden and improved chemotherapy response.

Conclusion

TRIM37 expression is associated with increased cell proliferation, regardless of subtype; however, it is strongly associated with reduced immune activity, worse response to chemotherapy, and poor prognosis in ER-positive/HER2-negative BC, whereas it was associated with better response to chemotherapy and no relationship with survival in TNBC. Our results provide critical insights into the clinical application of TRIM37-targeted therapies.